美洛西林舒巴坦治疗COPD急性加重期患者的临床评价  

Clinical evaluation of using mezlocillin sodium and sulbactam sodium for injection in treating acute exacerbation of COPD

作　　者：王家祥[1] 于卫东 于晓红[1] 卜宪聪[1] 

机构地区：[1]山东省日照市中医医院,山东日照276800 [2]山东省沂水县人民医院,山东沂水276400

出　　处：《中国当代医药》2010年第25期53-54,共2页China Modern Medicine

摘　　要：目的:探讨美洛西林舒巴坦治疗慢性阻塞性肺疾病(COPD)急性加重期患者的有效性和安全性。方法:将140例COPD急性加重期患者,随机分为治疗组和对照组,治疗组使用注射用美洛西林舒巴坦抗感染,对照组使用美洛西林抗感染。统计分析两组的临床有效率、细菌清除率、实验室资料。结果:治疗组和对照组临床有效率、细菌清除率相比,差异有统计学意义,P<0.05;实验室资料比较,差异无统计学意义,P>0.05。结论:美洛西林舒巴坦对COPD急性加重期患者有较好疗效,具有一定的临床价值。Objective：To evaluate the efficacy and security of using mezlocillin sodium and sulbactam sodium for injection in treating acute exacerbation of COPD.Methods：140 patients were randomly divided into two groups.The test group used mezlocillin sodium and sulbactam sodium for injection and the control group used mezlocillin sodium for resisting infection.Statisticaly analyzed the clinical efficacy,the rate of bacteria clearance,and the laboratory materials.Results：The difference of the laboratory materials between the two groups had no statistical meaning（P〉0.05）;There was statistical meaning about the difference in clinical efficacy and the rate of bacteria clearance between the two groups（P〈 0.05）.Conclusion：Mezlocillin sodium and sulbactam sodium for injection has good curative effect and certain clinical significance in treating acute exacerbation of COPD.

关 键 词：美洛西林舒巴坦 慢性阻塞性肺疾病急性加重期 疗效评价 

分 类 号：R974[医药卫生—药品]